LLY - Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses | Benzinga
Eli Lilly And Co (NYSE:LLY) faces renewed scrutiny as the FDA inspectors reveal additional manufacturing issues at its Branchburg, New Jersey plant.
In a recent inspection conducted by the FDA in July, eight deficiencies were identified, ranging from problems in tracking the manufacturing process to lapses in equipment calibration and facility maintenance.
The FDA inspection, prompted by Eli Lilly’s request for a change in the manufacture of migraine treatment Emgality, raised concerns about the overall quality control at the Branchburg facility.
Also Read: Eli Lilly’s Blockbuster Diabetes Drug Mounjaro Set To Enter New Markets Amid Manufacturing Boost.
Notably, other widely used drugs, such as diabetes medicine ...